Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 9
1966 5
1967 8
1968 4
1969 5
1970 5
1971 17
1972 11
1973 18
1974 13
1975 8
1976 21
1977 11
1978 10
1979 12
1980 13
1981 10
1982 12
1983 11
1984 5
1985 7
1986 4
1987 6
1988 7
1989 6
1990 4
1991 2
1992 2
1993 4
1994 4
1995 3
1996 7
1997 8
1998 6
1999 7
2000 9
2001 6
2002 8
2003 5
2004 5
2005 7
2006 7
2007 5
2008 8
2009 5
2010 5
2011 14
2012 7
2013 5
2014 6
2015 11
2016 8
2017 7
2018 4
2019 3
2020 8
2021 4
2022 5
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

427 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial.
Chu L, Acosta AM, Aazami H, Dennis P, De Valle O, Ehmer D Jr, Hedrick JA, Ansley JF. Chu L, et al. JAMA Netw Open. 2022 Jul 1;5(7):e2221699. doi: 10.1001/jamanetworkopen.2022.21699. JAMA Netw Open. 2022. PMID: 35834251 Free PMC article. Clinical Trial.
IMPORTANCE: Ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution seems to be efficacious and safe in treating acute otitis externa (AOE) compared with ciprofloxacin, 0.3%, or fluocinolone acetonide, 0.025%, otic solution alone. OBJEC …
IMPORTANCE: Ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution seems to be efficacious and safe in treati …
Pharmacokinetics of ciprofloxacin and fluocinolone acetonide otic solution in pediatric patients.
Spektor Z, Hussain I, Van Leeuwen RN, Goudy S, Esterhuizen K, Meyer R, Hedrick J. Spektor Z, et al. Am J Otolaryngol. 2022 Sep-Oct;43(5):103573. doi: 10.1016/j.amjoto.2022.103573. Epub 2022 Aug 5. Am J Otolaryngol. 2022. PMID: 35988360 Free article. Clinical Trial.
Blood samples were analyzed to detect ciprofloxacin and fluocinolone acetonide concentrations using two validated liquid chromatography-tandem mass spectrometry (LC-MS-MS) methods, with the lower limit of quantification for ciprofloxacin and fluocinolone a …
Blood samples were analyzed to detect ciprofloxacin and fluocinolone acetonide concentrations using two validated liquid chrom …
Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.
Pearson PA, Comstock TL, Ip M, Callanan D, Morse LS, Ashton P, Levy B, Mann ES, Eliott D. Pearson PA, et al. Ophthalmology. 2011 Aug;118(8):1580-7. doi: 10.1016/j.ophtha.2011.02.048. Ophthalmology. 2011. PMID: 21813090 Clinical Trial.
PURPOSE: We studied the 3-year efficacy and safety results of a 4-year study evaluating fluocinolone acetonide (FA) intravitreal implants in eyes with persistent or recurrent diabetic macular edema (DME). ...
PURPOSE: We studied the 3-year efficacy and safety results of a 4-year study evaluating fluocinolone acetonide (FA) intravitre …
Efficacy and safety of fluocinolone acetonide 0.025% otic solution in patients with otic eczema: a randomized, double-blind, placebo-controlled clinical trial.
Montoro V, Asensio C, Martínez Á, Lorente J, Rodríguez FJ, Montojo J, Gavilanes J, Sarría P, Langdon C, Prades E. Montoro V, et al. J Int Med Res. 2018 Oct;46(10):4050-4060. doi: 10.1177/0300060518765333. Epub 2018 Aug 24. J Int Med Res. 2018. PMID: 30141364 Free PMC article. Clinical Trial.
Objectives To assess the efficacy and safety of fluocinolone acetonide 0.025% otic solution versus placebo in treating patients with otic eczema. ...Incidence and severity of adverse events was similar between the fluocinolone and placebo groups. Conclusions …
Objectives To assess the efficacy and safety of fluocinolone acetonide 0.025% otic solution versus placebo in treating patient …
FLUOCINOLONE ACETONIDE IMPLANT FOR VOGT-KOYANAGI-HARADA DISEASE: Three-Year Outcomes of Efficacy and Safety.
Heo JW, Cho BJ, Goldstein DA, Sepah YJ, Do DV, Nguyen QD. Heo JW, et al. Retina. 2016 Nov;36(11):2124-2131. doi: 10.1097/IAE.0000000000001094. Retina. 2016. PMID: 27333235 Clinical Trial.
PURPOSE: To investigate the efficacy and safety of fluocinolone acetonide intravitreal implant in patients with Vogt-Koyanagi-Harada disease. METHODS: A post hoc, subgroup analysis on patients with Vogt-Koyanagi-Harada was performed using data sets from two multicen …
PURPOSE: To investigate the efficacy and safety of fluocinolone acetonide intravitreal implant in patients with Vogt-Koyanagi- …
Efficacy and Safety of Ciprofloxacin Plus Fluocinolone in Otitis Media With Tympanostomy Tubes in Pediatric Patients: A Randomized Clinical Trial.
Spektor Z, Pumarola F, Ismail K, Lanier B, Hussain I, Ansley J, Butehorn HF 3rd, Esterhuizen K, Byers J, Douglis F, Lansford B, Hernández FJ. Spektor Z, et al. JAMA Otolaryngol Head Neck Surg. 2017 Apr 1;143(4):341-349. doi: 10.1001/jamaoto.2016.3537. JAMA Otolaryngol Head Neck Surg. 2017. PMID: 28006041 Clinical Trial.
OBJECTIVE: To evaluate the efficacy and safety of topical ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution relative to ciprofloxacin, 0.3%, otic solution alone and fluocinolone acetonide, 0.025%, otic solution alone in the treatm …
OBJECTIVE: To evaluate the efficacy and safety of topical ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solut …
Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group. Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group. Ophthalmology. 2015 Oct;122(10):1976-86. doi: 10.1016/j.ophtha.2015.06.043. Epub 2015 Aug 19. Ophthalmology. 2015. PMID: 26298718 Free PMC article. Clinical Trial.
PURPOSE: To evaluate the risks and quality-of-life (QoL) outcomes of fluocinolone acetonide implant versus systemic therapy with corticosteroid and immunosuppression when indicated for intermediate uveitis, posterior uveitis, and panuveitis. ...CONCLUSIONS: These re …
PURPOSE: To evaluate the risks and quality-of-life (QoL) outcomes of fluocinolone acetonide implant versus systemic therapy wi …
Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
Holbrook JT, Sugar EA, Burke AE, Vitale AT, Thorne JE, Davis JL, Jabs DA; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Holbrook JT, et al. Am J Ophthalmol. 2016 Apr;164:29-36. doi: 10.1016/j.ajo.2015.12.028. Epub 2015 Dec 31. Am J Ophthalmol. 2016. PMID: 26748056 Free PMC article. Clinical Trial.
PURPOSE: To describe fluocinolone acetonide implant dissociations in the Multicenter Uveitis Steroid Treatment (MUST) Trial. ...
PURPOSE: To describe fluocinolone acetonide implant dissociations in the Multicenter Uveitis Steroid Treatment (MUST) Trial. . …
Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group; Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, Thorne JE. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, et al. Ophthalmology. 2015 Oct;122(10):1967-75. doi: 10.1016/j.ophtha.2015.06.042. Epub 2015 Aug 20. Ophthalmology. 2015. PMID: 26298715 Free PMC article. Clinical Trial.
PURPOSE: To compare the benefits of fluocinolone acetonide implant therapy versus systemic corticosteroid therapy supplemented (when indicated) with immunosuppression for intermediate uveitis, posterior uveitis, and panuveitis. ...Although macular edema improved sig …
PURPOSE: To compare the benefits of fluocinolone acetonide implant therapy versus systemic corticosteroid therapy supplemented …
427 results